Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | Dr. Gaurav D. ShahCEO & Director | -55,68k | 77,68k | Derivative Exercise and Sale | 1,69 - 3,09 | 1,47M | - |
| 2026-05-21 | Dr. Gaurav D. ShahCEO & Director | 20,81k | 35,18k | Derivative Exercise and Retained Stock | 1,69 | 1,47M | 1,44% |
| 2026-05-19 | Dr. Gaurav D. ShahCEO & Director | -2,41k | 7,26k | Vendita | 3,01 | 1,45M | -0,17% |
| 2026-05-19 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -662,00 | 2,00k | Vendita | 3,01 | 677,98k | -0,10% |
| 2026-05-19 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -384,00 | 1,16k | Vendita | 3,01 | 89,78k | -0,43% |
| 2026-05-13 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -3,36k | 12,12k | Vendita | 3,61 | 678,64k | -0,49% |
| 2026-05-13 | Dr. Gaurav D. ShahCEO & Director | -2,73k | 9,84k | Vendita | 3,61 | 1,45M | -0,19% |
| 2026-05-13 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -855,00 | 3,08k | Vendita | 3,61 | 90,16k | -0,94% |
| 2026-05-07 | Ms. Sarbani ChaudhuriChief Commercial & Medical Affairs Officer | -17,65k | 67,74k | Vendita | 3,84 | 141,59k | -11,08% |
| 2026-02-18 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -1,16k | 3,86k | Vendita | 3,34 | 91,02k | -1,26% |
| 2026-02-18 | Dr. Gaurav D. ShahCEO & Director | -5,99k | 19,99k | Vendita | 3,34 | 1,45M | -0,41% |
| 2026-02-18 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -1,38k | 4,59k | Vendita | 3,34 | 682,00k | -0,20% |
| 2026-02-13 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -12,25k | 40,58k | Vendita | 3,31 | 121,56k | -9,16% |
| 2026-02-13 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -3,73k | 12,34k | Vendita | 3,31 | 92,18k | -3,89% |
| 2026-02-13 | Dr. Gaurav D. ShahCEO & Director | -12,28k | 40,67k | Vendita | 3,31 | 1,09M | -1,11% |
| 2026-01-02 | Dr. Elisabeth BjorkInsider | 10,00k | 34,40k | Acquisto | 3,44 | 20,00k | 100,00% |
| 2025-11-18 | Dr. Jonathan SchwartzChief Science & Gene Therapy Officer | -2,55k | 7,59k | Vendita | 2,98 | 127,19k | -1,96% |
| 2025-11-18 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -1,65k | 4,91k | Vendita | 2,98 | 133,82k | -1,22% |
| 2025-11-18 | Dr. Gaurav D. ShahCEO & Director | -6,28k | 18,72k | Vendita | 2,98 | 1,18M | -0,53% |
| 2025-11-18 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -1,09k | 3,24k | Vendita | 2,98 | 65,92k | -1,62% |
| 2025-09-19 | RTW Investments, LPSocietà | -1,10M | 38,45M | Derivative Exercise and Sale | 3,11 - 40,03 | 18,19M | - |
| 2025-08-27 | Dr. Elisabeth BjorkInsider | 10,00k | 34,10k | Acquisto | 3,41 | 10,00k | - |
| 2025-08-18 | Dr. Gaurav D. ShahCEO & Director | -2,23k | 6,81k | Sale to Issuer | 3,05 | 1,19M | -0,19% |
| 2025-08-18 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -1,59k | 4,84k | Vendita | 3,00 - 3,07 | 135,46k | -1,16% |
| 2025-08-18 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -1,06k | 3,22k | Vendita | 3,00 - 3,07 | 55,92k | -1,86% |
| 2025-08-18 | Dr. Jonathan SchwartzChief Science & Gene Therapy Officer | -2,49k | 7,56k | Vendita | 3,00 - 3,07 | 124,66k | -1,95% |
| 2025-08-14 | Mr. Martin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | -12,11k | 36,56k | Vendita | 3,02 | 137,05k | -8,12% |
| 2025-08-14 | Mr. John C. MilitelloVP of Finance, Senior Controller & Treasurer and Principal Accounting Officer | -7,04k | 21,26k | Vendita | 3,02 | 56,98k | -11,00% |
| 2025-08-14 | Dr. Jonathan SchwartzChief Science & Gene Therapy Officer | -11,16k | 33,70k | Vendita | 3,02 | 124,23k | -8,24% |
| 2025-07-03 | Mr. Aaron OndreyInsider | -1,48k | 4,26k | Vendita | 2,88 | 10,53k | -12,31% |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
